Press Kit: PBM Reality 2026 Editorial Review Pending
Dataset summary
- Scope: Two first-party OmniRx datasets cross-referenced: 55 patient assistance programs (PAPs) and 50 insurer or drug-coverage formulary records.
- Time range: Q2 2026 (April through June 2026), with PBM industry context drawn from the FTC's July 2024 and January 2025 interim staff reports.
- Geographic scope: United States. Insurer coverage includes UnitedHealthcare, BCBS, Aetna, Cigna, Humana, Kaiser, Anthem, Ambetter, Molina, Medicare Part D, TRICARE, Medicaid, VA, Marketplace, and Medicare Advantage.
- Method: First-party editorial audit. Patient-assistance records are compiled from published program terms and carry last-verified dates; formulary records summarise publicly disclosed insurer formularies. The version of record is 2.0.2 (DOI 10.5281/zenodo.24322567).
- License: CC-BY 4.0; full dataset and aggregates available as machine-readable JSON.
- Lead author: Vincent, OmniRx Research. Editorial review by a credentialed clinician is pending.
Three quotable findings
"The modal patient assistance program in our database caps eligibility at 400 percent of the Federal Poverty Level, the same line the Affordable Care Act used for premium subsidies. That clustering is not coincidence. It tells you patient assistance programs are designed against visible regulatory thresholds, not against the actual distribution of patient need."
Attribute to: Vincent, OmniRx Research
"Sixty-six percent of patient assistance programs are run by the drug manufacturer, not by an independent nonprofit. A manufacturer PAP is a marketing-spend line item that covers only that manufacturer's portfolio. The patient ends up navigating a patchwork of brand-specific programs that the FTC's PBM reports describe at the wholesale layer and that we now document at the consumer-facing layer."
Attribute to: Vincent, OmniRx Research
Target outlets
KFF Health News (PBM and drug pricing beat); STAT News (Pharmalot, drug pricing investigations); ProPublica (health and prescription drug investigations); Bloomberg drug pricing desk; Healthcare Dive; Axios Vitals; the Drug Channels readership for industry context. Mark Cuban Cost Plus Drugs PR list welcome.
Headline numbers for editors
- 65.5% of PAPs are manufacturer-run (36 of 55).
- 16% of OmniRx drug-coverage entries are GLP-1 or weight-loss drugs (4 of 25).
Downloads
- Full study (HTML): omnirx.org/research/pbm-spread-pricing-2026
- Open dataset (JSON): data.json [CC-BY 4.0]
- Methodology: full methodology available on request via the media contact below
- Full chart pack (PNG + SVG): [CHART-PACK-PENDING] (available on request)
- Source records: assistance and formulary
Primary sources cited in the study
- FTC Interim Staff Report on Pharmacy Benefit Managers (Jul 2024)
- FTC Second Interim Staff Report on Prescription Drug Middlemen (Jan 2025)
- openFDA Drug API
- FDA Adverse Event Reporting System (FAERS)
- CMS Medicare Part D Formulary Files
- GAO Report on PBMs (GAO-19-498)
- KFF Health System Tracker
- Mark Cuban Cost Plus Drug Company
- Drug Channels Institute (Adam Fein)
- NIH National Library of Medicine, DailyMed
Media contact
Vincent, OmniRx Research
Email: vincent@deepsynthesis.org
Available for: written quotes (24 hour turnaround), data drill-down requests on any of the three datasets, on-record commentary on PBM structure, formulary tier opacity, patient assistance program design, and consumer-facing pharmacy navigation. We will route requests for clinical interpretation to a credentialed clinician once editorial review is finalized; for now, all clinical phrasing is conservative and editorial-review-pending.
Response time: typically same-day during ET business hours.
About OmniRx
OmniRx is an independent consumer pharmacy intelligence site at omnirx.org. We publish first-party drug interaction reference, formulary explainers, patient assistance program directories, and PBM industry research for U.S. patients. OmniRx is part of the DeepSynthesis Lattice, a constellation of niche research sites covering ecommerce, finance, education, and health verticals. We are not affiliated with any insurer, PBM, or pharmaceutical manufacturer.